GLP-1 drugs have shifted from medical to mainstream, and the impact is rippling far beyond health. From luxury to lifestyle, ...

The pioneering Danish drugmaker was once the most valuable company in Europe, but analysts say a number of missteps reversed ...

Wegovy, a brand name for semaglutide, is a GLP-1 inhibitor medication that targets the parts of the brain that regulate ...

Originally developed to treat type 2 diabetes and medical obesity, GLP-1 receptor agonists like tirzepatide and semaglutide ...

Sales of Danish drugmaker Novo Nordisk 's Wegovy and U.S. rival Eli Lilly's Mounjaro in India doubled in July from a month ...

China has massive unmet medical needs, Mike Doustdar, who took over as CEO of Novo Nordisk today, after previously leading ...

Novo Nordisk AS (NVO) reports significant sales and profit growth, driven by obesity care expansion and strategic ...

Novo Nordisk ( NVO -4.02%) stock imitated the company's leading product on Wednesday by slimming down in price. The Danish pharmaceutical's shares lost nearly 4% of their value following its latest ...

The news comes days after Novo cut its full-year outlook due to rising competition from copycat compounders, and named a new ...

Health-care companies fell as investors continued to retreat from formerly hot areas such as obesity-drug and vaccine makers. Shares of Novo Nordisk continued their slide despite reporting a ...

As announced July 29, Novo Nordisk NVO saw 18% sales growth and 40% operating profit growth at constant currencies in the ...

Novo Nordisk CFO Karsten Munk Knudsen tells Yahoo Finance the company understands the pressure it is under to deliver better ...